Brian C. Broderick’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $8.52M | Buy |
9,268
+1,052
| +13% | +$1.07M | 1.57% | 22 |
|
|
2025
Q4 | $8.83M | Buy |
8,216
+720
| +10% | +$688K | 1.67% | 22 |
|
|
2025
Q3 | $5.72M | Buy |
7,496
+985
| +15% | +$733K | 1.09% | 31 |
|
|
2025
Q2 | $5.08M | Buy |
6,511
+999
| +18% | +$776K | 1% | 33 |
|
|
2025
Q1 | $4.55M | Buy |
5,512
+2,832
| +106% | +$2.36M | 0.93% | 34 |
|
|
2024
Q4 | $2.07M | Sell |
2,680
-48
| -2% | -$39.7K | 0.41% | 44 |
|
|
2024
Q3 | $2.42M | Sell |
2,728
-24
| -0.9% | -$21.6K | 0.47% | 44 |
|
|
2024
Q2 | $2.49M | Buy |
2,752
+207
| +8% | +$166K | 0.51% | 44 |
|
|
2024
Q1 | $1.98M | Buy |
+2,545
| New | +$1.81M | 0.42% | 44 |
|
|
2021
Q4 | – | Sell |
-1,307
| Closed | -$303K | – | 81 |
|
|
2021
Q3 | $303K | Sell |
1,307
-50
| -4% | -$12.3K | 0.08% | 67 |
|
|
2021
Q2 | $312K | Hold |
1,357
| – | – | 0.08% | 67 |
|
|
2021
Q1 | $253K | Sell |
1,357
-450
| -25% | -$88K | 0.07% | 69 |
|
|
2020
Q4 | $306K | Hold |
1,807
| – | – | 0.09% | 65 |
|
|
2020
Q3 | $267K | Sell |
1,807
-125
| -6% | -$19.3K | 0.09% | 70 |
|
|
2020
Q2 | $318K | Hold |
1,932
| – | – | 0.11% | 70 |
|
|
2020
Q1 | $268K | Sell |
1,932
-125
| -6% | -$17.2K | 0.11% | 71 |
|
|
2019
Q4 | $271K | Hold |
2,057
| – | – | 0.09% | 75 |
|
|
2019
Q3 | $230K | Hold |
2,057
| – | – | 0.08% | 79 |
|
|
2019
Q2 | $228K | Sell |
2,057
-225
| -10% | -$26.5K | 0.08% | 78 |
|
|
2019
Q1 | $296K | Sell |
2,282
-566
| -20% | -$68.8K | 0.11% | 70 |
|
|
2018
Q4 | $330K | Sell |
2,848
-1,300
| -31% | -$145K | 0.14% | 67 |
|
|
2018
Q3 | $446K | Sell |
4,148
-950
| -19% | -$95K | 0.15% | 69 |
|
|
2018
Q2 | $435K | Hold |
5,098
| – | – | 0.16% | 65 |
|
|
2018
Q1 | $395K | Hold |
5,098
| – | – | 0.15% | 69 |
|
|
2017
Q4 | $431K | Sell |
5,098
-3,691
| -42% | -$314K | 0.16% | 67 |
|
|
2017
Q3 | $752K | Sell |
8,789
-100
| -1% | -$8.2K | 0.27% | 62 |
|
|
2017
Q2 | $732K | Sell |
8,889
-300
| -3% | -$24.5K | 0.27% | 64 |
|
|
2017
Q1 | $773K | Sell |
9,189
-50
| -0.5% | -$4K | 0.32% | 58 |
|
|
2016
Q4 | $680K | Buy |
9,239
+12
| +0.1% | +$894 | 0.29% | 64 |
|
|
2016
Q3 | $740K | Hold |
9,227
| – | – | 0.32% | 60 |
|
|
2016
Q2 | $726K | Hold |
9,227
| – | – | 0.31% | 61 |
|
|
2016
Q1 | $664K | Buy |
9,227
+700
| +8% | +$53K | 0.29% | 63 |
|
|
2015
Q4 | $718K | Buy |
8,527
+4,015
| +89% | +$333K | 0.32% | 66 |
|
|
2015
Q3 | $378K | Buy |
4,512
+12
| +0.3% | +$1.01K | 0.18% | 77 |
|
|
2015
Q2 | $376K | Sell |
4,500
-100
| -2% | -$7.62K | 0.16% | 79 |
|
|
2015
Q1 | $335K | Hold |
4,600
| – | – | 0.14% | 82 |
|
|
2014
Q4 | $317K | Sell |
4,600
-282
| -6% | -$19K | 0.13% | 82 |
|
|
2014
Q3 | $317K | Buy |
4,882
+282
| +6% | +$17.9K | 0.14% | 86 |
|
|
2014
Q2 | $286K | Sell |
4,600
-100
| -2% | -$5.97K | 0.13% | 86 |
|
|
2014
Q1 | $276K | Hold |
4,700
| – | – | 0.14% | 81 |
|
|
2013
Q4 | $240K | Hold |
4,700
| – | – | 0.12% | 85 |
|
|
2013
Q3 | $236K | Hold |
4,700
| – | – | 0.13% | 85 |
|
|
2013
Q2 | $230K | Buy |
+4,700
| New | +$256K | 0.14% | 85 |
|
Other funds holding LLY
VCM
VPM
Brian C. Broderick's LLY Position: Q1 2026 in Review
Brian C. Broderick increased its Eli Lilly (LLY) stake by 13% in Q1 2026, buying an estimated $1.07M and bringing the position to 9,268 shares worth $8.52M. The position accounts for 1.57% of the portfolio, ranked #22.
Brian C. Broderick first reported a position in LLY in Q2 2013 and has held it in 43 quarters since. The position peaked at $8.83M in Q4 2025. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Brian C. Broderick held 9,268 shares of Eli Lilly worth $8.52M as of Q1 2026.
- Brian C. Broderick bought 1,052 Eli Lilly shares in Q1 2026, an estimated $1.07M.
- Eli Lilly made up 1.57% of Brian C. Broderick's portfolio in Q1 2026, its #22 holding.
- Brian C. Broderick first reported a position in Eli Lilly in Q2 2013 and has held it in 43 quarters since.
- Brian C. Broderick's Eli Lilly position peaked at $8.83M in Q4 2025.
- 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Brian C. Broderick's 13F filing for Q1 2026, filed 7 May 2026.